{"title":"在brafv600e突变的结直肠癌中，KIAA1429的磷酸化通过激活FZD7-Wnt信号通路促进奥沙利铂耐药。","authors":"Taixuan Wan, Minyi He, Zhanzhen Liu, Yihang Zhou, Yebohao Zhou, Wei Xiao, Hao Xie, Shuangling Luo, Haoqi Zheng, Liang Kang, Yunxing Shi, Liang Huang","doi":"10.1186/s13046-025-03449-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The current standard therapeutic approach for colorectal cancer (CRC) is surgical operation and oxaliplatin (OXA)-based neoadjuvant chemotherapy. However, the acquisition of oxaliplatin resistance leads to an unfavorable prognosis in CRC. Therefore, there is an urgent need to elucidate the underlying mechanisms of oxaliplatin resistance.</p><p><strong>Methods: </strong>RNA-sequencing (RNA-seq) analysis of OXA-resistant CRC cell line was used to identify the driver of OXA resistance. Function of KIAA1429 in OXA-resistance was validated by in vivo and in vitro experiments. The underlying mechanism was investigated by Immunoprecipitation-Mass Spectrometry (IP-MS), Co-Immunoprecipitation (Co-IP), Immunofluorescence (IF), RNA immunoprecipitation (RIP) and RNA-seq.</p><p><strong>Results: </strong>KIAA1429 is significantly upregulated in oxaliplatin-resistant cell lines. However, we found that the expression level of KIAA1429 is not associated with the efficacy of neoadjuvant chemotherapy in colorectal cancer, indicating that the function of KIAA1429 is not solely determined by its expression level. We discovered that KIAA1429 exhibits differential nuclear and cytoplasmic distribution in colorectal cancer samples and that high cytoplasmic expression of KIAA1429 is associated with poor response to chemotherapy. Further investigation revealed that the nuclear-cytoplasmic distribution of KIAA1429 is regulated by BRAF-mediated phosphorylation. In vitro and in vivo experiments indicated that BRAF-mediated phosphorylation of KIAA1429 promotes oxaliplatin resistance by facilitating its aggregation in the cytoplasm. Mechanistically, we found that cytoplasmic KIAA1429 promotes WNT pathway activation by binding and stabilizing FZD7, thereby further enhancing cancer stemness and oxaliplatin resistance.</p><p><strong>Conclusions: </strong>This study elucidates the unique role of KIAA1429 phosphorylation in regulating its nuclear localization and function, offering novel insights into the mechanisms underlying OXA-resistance in CRC.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"44 1","pages":"187"},"PeriodicalIF":12.8000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225155/pdf/","citationCount":"0","resultStr":"{\"title\":\"Phosphorylation of KIAA1429 promotes oxaliplatin resistance through activating the FZD7-Wnt signaling in BRAF<sup>V600E</sup>-mutated colorectal cancer.\",\"authors\":\"Taixuan Wan, Minyi He, Zhanzhen Liu, Yihang Zhou, Yebohao Zhou, Wei Xiao, Hao Xie, Shuangling Luo, Haoqi Zheng, Liang Kang, Yunxing Shi, Liang Huang\",\"doi\":\"10.1186/s13046-025-03449-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The current standard therapeutic approach for colorectal cancer (CRC) is surgical operation and oxaliplatin (OXA)-based neoadjuvant chemotherapy. However, the acquisition of oxaliplatin resistance leads to an unfavorable prognosis in CRC. Therefore, there is an urgent need to elucidate the underlying mechanisms of oxaliplatin resistance.</p><p><strong>Methods: </strong>RNA-sequencing (RNA-seq) analysis of OXA-resistant CRC cell line was used to identify the driver of OXA resistance. Function of KIAA1429 in OXA-resistance was validated by in vivo and in vitro experiments. The underlying mechanism was investigated by Immunoprecipitation-Mass Spectrometry (IP-MS), Co-Immunoprecipitation (Co-IP), Immunofluorescence (IF), RNA immunoprecipitation (RIP) and RNA-seq.</p><p><strong>Results: </strong>KIAA1429 is significantly upregulated in oxaliplatin-resistant cell lines. However, we found that the expression level of KIAA1429 is not associated with the efficacy of neoadjuvant chemotherapy in colorectal cancer, indicating that the function of KIAA1429 is not solely determined by its expression level. We discovered that KIAA1429 exhibits differential nuclear and cytoplasmic distribution in colorectal cancer samples and that high cytoplasmic expression of KIAA1429 is associated with poor response to chemotherapy. Further investigation revealed that the nuclear-cytoplasmic distribution of KIAA1429 is regulated by BRAF-mediated phosphorylation. In vitro and in vivo experiments indicated that BRAF-mediated phosphorylation of KIAA1429 promotes oxaliplatin resistance by facilitating its aggregation in the cytoplasm. Mechanistically, we found that cytoplasmic KIAA1429 promotes WNT pathway activation by binding and stabilizing FZD7, thereby further enhancing cancer stemness and oxaliplatin resistance.</p><p><strong>Conclusions: </strong>This study elucidates the unique role of KIAA1429 phosphorylation in regulating its nuclear localization and function, offering novel insights into the mechanisms underlying OXA-resistance in CRC.</p>\",\"PeriodicalId\":50199,\"journal\":{\"name\":\"Journal of Experimental & Clinical Cancer Research\",\"volume\":\"44 1\",\"pages\":\"187\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225155/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Experimental & Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13046-025-03449-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental & Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13046-025-03449-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Phosphorylation of KIAA1429 promotes oxaliplatin resistance through activating the FZD7-Wnt signaling in BRAFV600E-mutated colorectal cancer.
Background: The current standard therapeutic approach for colorectal cancer (CRC) is surgical operation and oxaliplatin (OXA)-based neoadjuvant chemotherapy. However, the acquisition of oxaliplatin resistance leads to an unfavorable prognosis in CRC. Therefore, there is an urgent need to elucidate the underlying mechanisms of oxaliplatin resistance.
Methods: RNA-sequencing (RNA-seq) analysis of OXA-resistant CRC cell line was used to identify the driver of OXA resistance. Function of KIAA1429 in OXA-resistance was validated by in vivo and in vitro experiments. The underlying mechanism was investigated by Immunoprecipitation-Mass Spectrometry (IP-MS), Co-Immunoprecipitation (Co-IP), Immunofluorescence (IF), RNA immunoprecipitation (RIP) and RNA-seq.
Results: KIAA1429 is significantly upregulated in oxaliplatin-resistant cell lines. However, we found that the expression level of KIAA1429 is not associated with the efficacy of neoadjuvant chemotherapy in colorectal cancer, indicating that the function of KIAA1429 is not solely determined by its expression level. We discovered that KIAA1429 exhibits differential nuclear and cytoplasmic distribution in colorectal cancer samples and that high cytoplasmic expression of KIAA1429 is associated with poor response to chemotherapy. Further investigation revealed that the nuclear-cytoplasmic distribution of KIAA1429 is regulated by BRAF-mediated phosphorylation. In vitro and in vivo experiments indicated that BRAF-mediated phosphorylation of KIAA1429 promotes oxaliplatin resistance by facilitating its aggregation in the cytoplasm. Mechanistically, we found that cytoplasmic KIAA1429 promotes WNT pathway activation by binding and stabilizing FZD7, thereby further enhancing cancer stemness and oxaliplatin resistance.
Conclusions: This study elucidates the unique role of KIAA1429 phosphorylation in regulating its nuclear localization and function, offering novel insights into the mechanisms underlying OXA-resistance in CRC.
期刊介绍：
The Journal of Experimental & Clinical Cancer Research is an esteemed peer-reviewed publication that focuses on cancer research, encompassing everything from fundamental discoveries to practical applications.
We welcome submissions that showcase groundbreaking advancements in the field of cancer research, especially those that bridge the gap between laboratory findings and clinical implementation. Our goal is to foster a deeper understanding of cancer, improve prevention and detection strategies, facilitate accurate diagnosis, and enhance treatment options.
We are particularly interested in manuscripts that shed light on the mechanisms behind the development and progression of cancer, including metastasis. Additionally, we encourage submissions that explore molecular alterations or biomarkers that can help predict the efficacy of different treatments or identify drug resistance. Translational research related to targeted therapies, personalized medicine, tumor immunotherapy, and innovative approaches applicable to clinical investigations are also of great interest to us.
We provide a platform for the dissemination of large-scale molecular characterizations of human tumors and encourage researchers to share their insights, discoveries, and methodologies with the wider scientific community.
By publishing high-quality research articles, reviews, and commentaries, the Journal of Experimental & Clinical Cancer Research strives to contribute to the continuous improvement of cancer care and make a meaningful impact on patients' lives.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
